BBA
MDGL icon

Baader Bank Aktiengesellschaft’s Madrigal Pharmaceuticals MDGL Stock Holding History

Baader Bank Aktiengesellschaft’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-902
Closed -$525K – 502
2025
Q4 		$525K Sell
902
-1,033
-53% -$528K 0.04% 281
2025
Q3 		$885K Buy
+1,935
New +$722K 0.06% 196

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baader Bank Aktiengesellschaft's MDGL Position: Q1 2026 in Review

Baader Bank Aktiengesellschaft sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2026, closing a stake of 902 shares — an estimated $525K sold.

Baader Bank Aktiengesellschaft first reported a position in MDGL in Q3 2025 and held it in 2 quarters. The position peaked at $885K in Q3 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Baader Bank Aktiengesellschaft reported no remaining Madrigal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Baader Bank Aktiengesellschaft sold 902 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $525K.
  • Baader Bank Aktiengesellschaft first reported a position in Madrigal Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Baader Bank Aktiengesellschaft's Madrigal Pharmaceuticals position peaked at $885K in Q3 2025.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Baader Bank Aktiengesellschaft's 13F filing for Q1 2026, filed 8 May 2026.